SfN 2025 – High-Content Imaging Platforms for Assessing Neuroplasticity in Early-Stage Drug Discovery

Accelerating Neuroplasticity Screening with Scalable in vitro Models

Structural and functional neuroplasticity is a key driver of brain development and adaptation—but studying it effectively at early stages of drug discovery remains challenging. This poster highlights Sygnature Discovery’s semi-automated high-content imaging platform that quantifies neurite outgrowth across PC12, SH-SY5Y, and primary neuron models.

The result? A robust, scalable tool for phenotypic screening of neuroplasticity modulators—accelerating the identification of new therapies for neuropsychiatric and neurodegenerative disorders, with flexibility to expand into metabolism, neuroinflammation, and beyond.

Download the free poster to see how this platform bridges early discovery and translational neuroscience.